London, UK – January 28, 2025 – Vortex Biotech Holdings, a pioneering oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as its new Non-Executive Chairman. This high-profile addition to Vortex’s leadership team signals a significant step forward as the company prepares for its next phase of growth and commercialisation.

Nigel Brooksby brings a wealth of experience from a distinguished career in the pharmaceutical and biotechnology industries. His notable roles include Chairman and CEO of Sanofi UK, where he was instrumental in elevating the company to a top-tier global pharmaceutical business. He also held senior positions at GSK and Pfizer International USA, accumulating a deep understanding of the financial, operational, and strategic intricacies of the life sciences sector. His extensive global network is expected to be invaluable to Vortex.

“Vortex has a bright future ahead,” commented Nigel Brooksby, expressing his enthusiasm for contributing to the company’s success. He highlighted the transformative potential of liquid biopsy technologies, particularly those utilizing circulating tumour cells, in revolutionising cancer diagnosis and treatment by enabling more personalised therapies.

Paul Reeves, Managing Director of Vortex, emphasised the strategic importance of Brooksby’s appointment, noting his expertise in guiding companies from innovation to commercialisation in complex international markets. He stated that Brooksby’s leadership positions Vortex for rapid growth as it seeks to build commercial traction for its liquid biopsy offering.

Vortex’s liquid biopsy platform offers a less invasive, more patient-friendly alternative to traditional tissue biopsies, while delivering equally accurate results. This innovative approach promises to make cancer diagnosis and monitoring more accessible, faster, and less stressful for patients.

Dr. Ilian Iliev, CEO of EMV Capital PLC and outgoing Chairman, warmly welcomed Brooksby, acknowledging his extensive market knowledge and commercial expertise. He expressed confidence that with Brooksby’s appointment, coupled with Vortex’s advanced technology, the company is poised for significant growth in advancing precision medicine and ultimately improving cancer care.